About: Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2010.09707.x/pdf
Description	To retrospectively evaluate the effect of subsequent tyrosine kinase inhibitors (TKIs) after first-line bevacizumab + interferon-alfa2a (IFN) or IFN + placebo in the phase III AVOREN (Avastin and Roferon in Renal Cell Carcinoma) trial. Multiple active treatment options are available for patients with mRCC. Current data suggest that it is difficult to use these therapies in combination due to toxicity concerns. The ability to use these active therapies sequentially provides the potential for improved patient outcomes. To retrospectively evaluate the effect of subsequent tyrosine kinase inhibitors (TKIs) after first-line bevacizumab + interferon-alfa2a (IFN) or IFN + placebo in the phase III AVOREN (Avastin and Roferon in Renal Cell Carcinoma) trial. Multiple active treatment options are available for patients with mRCC. Current data suggest that it is difficult to use these therapies in combination due to toxicity concerns. The ability to use these active therapies sequentially provides the potential for improved patient outcomes. (en)
Title	Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial (en)
skos:prefLabel	Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial (en)
skos:notation	RIV/00179906:_____/11:10110344!RIV12-MZ0-00179906
http://linked.open...avai/predkladatel	Fakultní nemocnice Hradec Králové
http://linked.open...avai/riv/aktivita	N S
http://linked.open...avai/riv/aktivity	N, S
http://linked.open...iv/cisloPeriodika	2
http://linked.open...vai/riv/dodaniDat	2012
http://linked.open...aciTvurceVysledku	Melichar, Bohuslav
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Fakultní nemocnice Hradec Králové
http://linked.open...dnocenehoVysledku	219160
http://linked.open...ai/riv/idVysledku	RIV/00179906:_____/11:10110344
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	tyrosine kinase inhibitors; sequencing; overall survival; metastatic RCC; bevacizumab (en)
http://linked.open.../riv/klicoveSlovo	tyrosine kinase inhibitors overall survival metastatic RCC bevacizumab sequencing
http://linked.open...odStatuVydavatele	GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV	[ACDFEF01413B]
http://linked.open...i/riv/nazevZdroje	BJU International
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	8 (xsd:int)
http://linked.open...UplatneniVysledku	2011
http://linked.open...v/svazekPeriodika	107
http://linked.open...iv/tvurceVysledku	Melichar, Bohuslav Bajetta, Emilio Bellmunt, Joaquim Bracarda, Sergio Escudier, Bernard Négrier, Sylvie Ravaud, Alain Sneller, Vesna
http://linked.open...ain/vavai/riv/wos	000285922200005
issn	1464-4096
number of pages	6 (xsd:int)
http://bibframe.org/vocab/doi	10.1111/j.1464-410X.2010.09707.x
is http://linked.open...avai/riv/vysledek of	Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 78 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software